Tesamorelin — Benefits & User Experiences
GHRH analogue approved for HIV-associated lipodystrophy. Reduces visceral fat accumulation through sustained GH stimulation; available as Egrifta.
23 anonymous reports
Side EffectsMental HealthSourcingPeptides for Weight LossPeptides for Muscle GrowthTesamorelinSuccess StoriesStacking
Also known as:
egriftatesamorelin acetatetesa
often mentioned with:
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Page 1 of 2
PreviousNext
Community Q&A
- What is tesamorelin used for?
- Community accounts split between its FDA-approved use (HIV-associated lipodystrophy) and general body composition goals. For lipodystrophy accounts, tesamorelin is described as producing significant visceral fat reduction over 3–6 months — a distinct and meaningful outcome for users affected by HIV medication-related fat redistribution. For general use accounts, tesamorelin is framed as a GHRH analogue producing visceral fat reduction and GH stimulation similar to sermorelin but with a stronger evidence base and more predictable response.
- How does tesamorelin compare to sermorelin?
- Community accounts that have used both describe tesamorelin as producing a stronger and more consistent GH response, particularly for visceral fat reduction. Sermorelin accounts tend to be more general and wellness-focused; tesamorelin accounts are more frequently targeted at specific visceral fat concerns. Cost is consistently cited in tesamorelin accounts — it is more expensive than sermorelin, limiting its use to those with specific therapeutic goals. Both are described as gradual compounds requiring months for full effect.